Bioforce Nanosciences Holdings, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-18. Between them they name 2 people. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Scott Mager, effective 2026-06-15
Effective June 15, 2026, the Board of Directors appointed Scott Mager as Directors of the Company.
Appointed: Richard Kaiser, Chief Executive Officer
Officer Appointment On June 17, 2026, the Company's Board of Directors appointed Richard Kaiser as the Company's interim Chief Executive Officer.
Find people with the same kind of experience as the Chief Executive Officer at Bioforce Nanosciences Holdings, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Bioforce Nanosciences Holdings, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Bioforce Nanosciences Holdings, Inc. is in the news or changes leadership.
Get an alert when Bioforce Nanosciences Holdings, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Bioforce Nanosciences Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.